CoChat

The Ataxia Telangiectasia–Mutated Target Site Ser18 Is Required for p53-Mediated Tumor Suppression

Open access
Armata, Heather L., Garlick, David S., Sluss, Hayla K. · 2007 · Cancer Research
Cited by 68

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

The p53 tumor suppressor is phosphorylated at multiple sites within its NH2-terminal region. One of these phosphorylation sites (mouse Ser18 and human Ser15) is a substrate for the ataxia telangiectasia–mutated (ATM) and ATM-related (ATR) protein kinases. Studies of p53S18A mice (with a germ-line mutation that replaces Ser18 with Ala) have indicated that ATM/ATR phosphorylation of p53 Ser18 is required for normal DNA damage–induced PUMA expression and apoptosis but not for DNA damage–induced cell cycle arrest. Unlike p53-null mice, p53S18A mice did not succumb to early-onset tumors. This finding suggested that phosphorylation of p53 Ser18 was not required for p53-dependent tumor suppression. Here we report that the survival of p53S18A mice was compromised and that they spontaneously developed late-onset lymphomas (between ages 1 and 2 years). These mice also developed several malignancies, including fibrosarcoma, leukemia, leiomyosarcoma, and myxosarcoma, which are unusual in p53 mutant mice. Furthermore, we found that lymphoma development was linked with apoptotic defects. In addition, p53S18A animals exhibited several aging-associated phenotypes early, and murine embryonic fibroblasts from these animals underwent early senescence in culture. Together, these data indicate that the ATM/ATR phosphorylation site Ser18 on p53 contributes to tumor suppression in vivo. [Cancer Res 2007;67(24):11696–703]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-1610

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 68

Metadata

Authors
Armata, H. L., Garlick, D. S., & Sluss, H. K.
Venue
Cancer Research
Published
2007-12-15
Volume
67
Issue
24
Pages
11696-11703
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2107334822
Cited by
68
References
22
FWCI
3.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Ataxia Telangiectasia–Mutated Target Site Ser18 Is Required for p53-Mediated Tumor Suppression. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-1610
The paper
Armata, H. L., Garlick, D. S., & Sluss, H. K. (2007). The Ataxia Telangiectasia–Mutated Target Site Ser18 Is Required for p53-Mediated Tumor Suppression. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-1610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.